# A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

> **NCT01859741** · PHASE1,PHASE2 · TERMINATED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 172 (actual)

## Conditions studied

- Stage IV Small Cell Lung Cancer

## Interventions

- **DRUG:** OMP-59R5
- **DRUG:** Etoposide
- **DRUG:** Placebo
- **DRUG:** Cisplatin or Carboplatin

## Key facts

- **NCT ID:** NCT01859741
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01-07
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-05-08
- **Target enrollment:** 172 (ACTUAL)
- **Why stopped:** OMP-59R5 did not improve PFS.
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859741, "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01859741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*